Literature DB >> 27259485

Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration.

M Julia García-Fuster1,2, Jesús A García-Sevilla3,4.   

Abstract

RATIONALE: Fas-associated death domain (FADD) is an adaptor of death receptors that can also induce anti-apoptotic actions through its phosphorylated form (p-FADD). Activation of monoamine receptors, indirect targets of classic anti-depressant drugs (ADs), reduced FADD and increased p-FADD and p-FADD/FADD ratio in brain.
OBJECTIVES: To ascertain whether ADs, which indirectly regulate monoamine receptors, modulate FADD protein forms to promote anti-apoptotic actions.
METHODS: The effects of selected norepinephrine transporter (NET), serotonin transporter (SERT), monoamine oxidase (MAO) inhibitors, atypical ADs, and electroconvulsive shock (ECS) or behavioral procedures (forced swim test, FST) on FADD forms and pro-survival FADD-like interleukin-1β-converting enzyme-inhibitory protein (FLIP-L) and phosphoprotein enriched in astrocytes of 15 kDa (p-PEA-15) contents were assessed in rat brain cortex by western blot analysis.
RESULTS: Acute NET (e.g., nisoxetine) but not SERT (e.g., fluoxetine) inhibitors decreased cortical FADD (up to 37 %) and increased p-FADD/FADD ratio (up to 1.9-fold). Nisoxetine effects were prevented by α2-antagonist RX-821002, suggesting the involvement of presynaptic α2-autoreceptors. Immobility time in the FST correlated with increases of pro-apoptotic FADD and decreases of anti-apoptotic p-FADD. The MAO-A/B inhibitor phenelzine decreased FADD (up to 33 %) and increased p-FADD (up to 65 %) and p-FADD/FADD (up to 2.4-fold). Other MAO inhibitors (clorgyline, Ro 41-1049, rasagiline), atypical ADs (ketamine and mirtazapine), or ECS did not modulate cortical FADD. Chronic (14 days) desipramine and fluoxetine, but not phenelzine, increased p-FADD (up to 59 %), p-FADD/FADD ratio (up to 1.8-fold), and pro-survival p-PEA-15 (up to 46 %) in rat brain cortex.
CONCLUSIONS: Multifunctional FADD protein, through an increased p-FADD/FADD ratio, could participate in the mechanisms of anti-apoptotic actions induced by ADs.

Entities:  

Keywords:  Anti-depressant drugs; Electroconvulsive shock; FADD and p-FADD; Forced swim test; Neuroplasticity; Neuroprotection

Mesh:

Substances:

Year:  2016        PMID: 27259485     DOI: 10.1007/s00213-016-4342-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  76 in total

Review 1.  Presynaptic autoreceptors in the third decade: focus on alpha2-adrenoceptors.

Authors:  K Starke
Journal:  J Neurochem       Date:  2001-08       Impact factor: 5.372

2.  Desipramine selectively potentiates norepinephrine-elicited ERK1/2 activation through the α2A adrenergic receptor.

Authors:  Christopher Cottingham; Adrian Jones; Qin Wang
Journal:  Biochem Biophys Res Commun       Date:  2012-03-03       Impact factor: 3.575

3.  Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA).

Authors:  G B Baker; J T Wong; J M Yeung; R T Coutts
Journal:  J Affect Disord       Date:  1991-03       Impact factor: 4.839

Review 4.  5-HT receptor regulation of neurotransmitter release.

Authors:  Klaus B Fink; Manfred Göthert
Journal:  Pharmacol Rev       Date:  2007-12       Impact factor: 25.468

Review 5.  Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer.

Authors:  Mahaveer S Bhojani; Guoan Chen; Brian D Ross; David G Beer; Alnawaz Rehemtulla
Journal:  Cell Cycle       Date:  2005-11-20       Impact factor: 4.534

6.  Selective increase of alpha2A-adrenoceptor agonist binding sites in brains of depressed suicide victims.

Authors:  L F Callado; J J Meana; B Grijalba; A Pazos; M Sastre; J A García-Sevilla
Journal:  J Neurochem       Date:  1998-03       Impact factor: 5.372

Review 7.  The neuropsychological hypothesis of antidepressant drug action revisited.

Authors:  Niki Antypa; Raffaella Calati; Alessandro Serretti
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

8.  Apoptosis-related proteins and proliferation markers in the orbitofrontal cortex in major depressive disorder.

Authors:  Jose J Miguel-Hidalgo; Angela Whittom; Ashley Villarreal; Madhav Soni; Ashish Meshram; Jason C Pickett; Grazyna Rajkowska; Craig A Stockmeier
Journal:  J Affect Disord       Date:  2014-02-10       Impact factor: 4.839

9.  Fluoxetine potentiation of methylphenidate-induced gene regulation in striatal output pathways: potential role for 5-HT1B receptor.

Authors:  Vincent Van Waes; Sarah Ehrlich; Joel A Beverley; Heinz Steiner
Journal:  Neuropharmacology       Date:  2014-09-16       Impact factor: 5.250

10.  FLIP(L) protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death.

Authors:  Era Taoufik; Samuel Valable; Georg J Müller; Michael L Roberts; Didier Divoux; Antoine Tinel; Anda Voulgari-Kokota; Vivian Tseveleki; Fiorella Altruda; Hans Lassmann; Edwige Petit; Lesley Probert
Journal:  J Neurosci       Date:  2007-06-20       Impact factor: 6.167

View more
  6 in total

1.  Increased negative affect when combining early-life maternal deprivation with adolescent, but not adult, cocaine exposure in male rats: regulation of hippocampal FADD.

Authors:  Cristian Bis-Humbert; Rubén García-Cabrerizo; M Julia García-Fuster
Journal:  Psychopharmacology (Berl)       Date:  2020-10-27       Impact factor: 4.530

Review 2.  Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.

Authors:  Tapan Behl; Dapinder Kaur; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Gokhan Zengin; Felicia Liana Andronie-Cioara; Mirela Marioara Toma; Simona Bungau; Adrian Gheorghe Bumbu
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

3.  Decreased cortical FADD protein is associated with clinical dementia and cognitive decline in an elderly community sample.

Authors:  Alfredo Ramos-Miguel; Jesús A García-Sevilla; Alasdair M Barr; Thomas A Bayer; Peter Falkai; Sue E Leurgans; Julie A Schneider; David A Bennett; William G Honer; M Julia García-Fuster
Journal:  Mol Neurodegener       Date:  2017-03-20       Impact factor: 14.195

4.  MRI-Based Classification Models in Prediction of Mild Cognitive Impairment and Dementia in Late-Life Depression.

Authors:  Aleksandra K Lebedeva; Eric Westman; Tom Borza; Mona K Beyer; Knut Engedal; Dag Aarsland; Geir Selbaek; Asta K Haberg
Journal:  Front Aging Neurosci       Date:  2017-02-02       Impact factor: 5.750

5.  Revisiting the antidepressant-like effects of desipramine in male and female adult rats: sex disparities in neurochemical correlates.

Authors:  Sandra Ledesma-Corvi; M Julia García-Fuster
Journal:  Pharmacol Rep       Date:  2022-06-02       Impact factor: 3.919

Review 6.  Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine.

Authors:  Dmitriy Matveychuk; Erin M MacKenzie; David Kumpula; Mee-Sook Song; Andrew Holt; Satyabrata Kar; Kathryn G Todd; Paul L Wood; Glen B Baker
Journal:  Cell Mol Neurobiol       Date:  2021-04-10       Impact factor: 5.046

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.